Neurol. praxi. 2010;11(4):256-259

Demyelination and remyelination in CNS

MUDr.Pavel Hradílek, Ph.D.
MS centrum, Neurologická klinika FN Ostrava

Author summarizes recent knowledge about demyelination and remyelination in the central nervous system with intention to pathophysiological

phenomenons, which determine these processes. New MRI methods enabling images of demyelinated and remyelinated

brain and spinal cord tissue are shown. Author brings contemporary therapeutic options of support of remyelination in tissue affected

with demyelinating process.

Keywords: myelin, central nervous system, demyelination, remyelination, multiple sclerosis

Published: October 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hradílek P. Demyelination and remyelination in CNS. Neurol. praxi. 2010;11(4):256-259.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Blanchette F, Neuhaus O. Glatiramer Acetate. Evidence for a dual mechanism of action. J Neurol 2008; 255(Suppl 1): 26-36. Go to original source... Go to PubMed...
    2. Bot JCJ, Barkhof F. Spinal cord MRI in multiple sclerosis: conventional and non-conventional MRI techniques. Neuroimag Clin N Am 2009; 19: 81-99. Go to original source... Go to PubMed...
    3. Dhib-Jalbut S. Pathogenesis of myelin/oligodendrocyte damane in multiple sclerosis. Neurology 2007; 68(Suppl 3): S13-S21. Go to original source... Go to PubMed...
    4. Dwyer M, Bergsland N, Hussein S, Durfee J, Wack D, Zivadinov R. A sensitive, noise-resistant method for identifying focal demyelination and remyelination in patients with multiple sclerosis via voxel-wise changes in magnetization transfer ratio. J Neurol Sci 2009; 282: 86-95. Go to original source... Go to PubMed...
    5. Franklin RJM, Kotter MR. The biology of CNS remyelination. The key to therapeutic advances. J Neurol 2008; 255(Suppl 1): 19-25. Go to original source... Go to PubMed...
    6. Giacomini PS, Levesque IR, Ribeiro L, Narayanan S, Francis SJ, Pike B, Arnold DL. Measuring demyelination and remyelination in acute multiple sclerosis lesion voxels. Arch Neurol 2009; 66: 375-381. Go to original source... Go to PubMed...
    7. Goldschmidt T, Antel J, König FB, Brück W, Kuhlmann T. Remyelination capacity of the MS brain decreases with disease chronicity. Neurology 2009; 72: 1914-1921. Go to original source... Go to PubMed...
    8. Hafler DA, Slavik JM, Anderson DE, O´Connor KC, DeJager P, Beacher-Allan C. Multiple Sclerosis. Immunol Rev 2005; 204: 208-231. Go to original source... Go to PubMed...
    9. Havrdová E. Roztroušená skleróza. Triton 2002: 114.
    10. Kirov I, Patil V, Babb J, Rusinek H, Herbert J, Gonen O. MR spectroscopy indicates diffuse multiple sclerosis activity during remission. J Neurol Neurosurg Psychiatry 2009; 80(12): 1330-1336. Go to original source... Go to PubMed...
    11. Li WW, PenderisJ, Zhao C, Schumacher M, Franclin RJM. Females remyelinate more efficiently than males following demyelination in the aged but not young adult CNS. Exp Neurol 2006; 202: 250-254. Go to original source... Go to PubMed...
    12. Maršala J. Systematická a funkčná neuroanatómia. Osveta 1985: 784.
    13. Prineas JW, Connell F. Remyelination in multiple sclerosis. Ann Neurol 1979; 5: 22-31. Go to original source... Go to PubMed...
    14. Prineas JW, Barnard RO, Kwon EE, et al. Multiple sclerosis: remyelination of nascent lesions. Ann Neurol 1993; 33: 137-151. Go to original source... Go to PubMed...
    15. Raine CS, Wu E. Multiple sclerosis: remyelination in acute lesions. J Neuropathol Exp Neurol 1993; 52: 199-204. Go to original source...
    16. Stadelmann Ch, Brück W. Interplay between mechanisms of damage and repair in multiple sclerosis. J Neurol 2008; 255(Suppl 1): 12-18. Go to original source... Go to PubMed...
    17. Tegla CA, Cudrici C, Rus V, Ito T, Vlaicu S, Singh A, Rus H. Neuroprotective effects of the complement terminal pathway during demyelination: implications for oligodendrocyte survival. J Neuroimmunol 2009; 18: 213(1-2): 3-11. Go to original source... Go to PubMed...
    18. Williams PL, Warwick R, Dyson M, Bannister LH. Gray´s anatomy, thirty-seventh edition. Churchil Livingstone 1989: 1600.
    19. Woodruff RH, Fruttiger M, Richardson WD, Franklin RJM. Platelet-derived growth factor regulates oligodendrocyte progenitor numbers in adult CNS and their response following CNS demyelination. Mol Cell Neurosci 2004; 25: 252-262. Go to original source... Go to PubMed...
    20. Yang J, Rostami A, Zhang GX. Cellular remyelination therapy in multiple sclerosis. J Neurol Sci 2009; 276: 1-5. Go to original source... Go to PubMed...
    21. Zapletalová O. Léčba časných stadií roztroušené sklerózy mozkomíšní. Remedia 2009; 19: 198-204.
    22. Zivadinov R, Dwyer MG, Bergsland N, Hussein S, Cox J, Durfee J, Nayyar N, Hojnacki D, Hashmi K, Heininen-Brown M, Chouhfeh L, Carl E, Weinstock-Guttman B. Natalizumab (Tysabri) promotes remyelination in patients with multiple sclerosis. A voxel-wise magnetization transfer imaging casecontrol study. Neurology 2009; 72(Suppl 3): A140.

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.